The GP will take a detailed history including: Current medications and supplements (particularly B12 injections or high-dose oral preparations) Alcohol consumption and risk factors for liver disease Personal or family history of haematological disorders or cancer Symptoms suggesting underlying pathology Recommended investigations: Patients with unexplained elevated B12 should undergo: Repeat B12 measurement to confirm persistence, ideally timed away from recent injections or high-dose supplements Full blood count (FBC): To identify polycythaemia, leucocytosis, or other haematological abnormalities Liver function tests (LFTs): Including ALT, AST, ALP, bilirubin, and albumin to assess hepatic function Renal function tests: Urea, creatinine, and estimated glomerular filtration rate (eGFR) Lactate dehydrogenase (LDH): Elevated in haemolysis, liver disease, and some malignancies Further investigations may include: Abdominal ultrasound or CT scanning if liver disease or malignancy suspected Haematology referral for bone marrow examination if myeloproliferative disorder considered Liaison with the laboratory if results conflict with the clinical picture, as immunoassay interference (e.g., macro-B12) may occur In specialist settings, measurement of holo-transcobalamin or B12-binding proteins may be considered The urgency of investigation depends on clinical features and suspected underlying conditions

Products from unregulated online vendors are not manufactured under pharmaceutical standards, may contain incorrect concentrations or be mislabeled, have no guarantee of sterility or freedom from contamination, are often produced overseas in facilities with unknown quality controls, and carry zero accountability if something goes wrong
Niini T, Laakso A, Tanskanen P, Niemel M, Luostarinen T
[30] For example, cyanocobalamin can be converted to its analog cobalamins via reduction to B 12s , followed by the addition of the corresponding alkyl halides, acyl halides, alkene or alkyne
As early as 1996, a study entitled Reduced intravenous glutathione in the treatment of early Parkinsons disease found that the progression of PD was reduced, and symptoms improved by 42% after only 30 days of treatment